AURA (Aura Biosciences) Total Liabilities: $30.43 Mil (As of Mar. 2026)


AURA Aura Biosciences Inc AURA
34 GF Score
Price $6.84
! 3 Warning Signs
View Full Analysis

What is Aura Biosciences Total Liabilities?

Aura Biosciences AURA -2.15% 34 Total Liabilities is $30.43 Mil as of Mar. 2026. GuruFocus rates AURA with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Aura Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 was $30.43 Mil.

Aura Biosciences's quarterly Total Liabilities declined from Sep. 2025 ($33.36 Mil) to Dec. 2025 ($32.52 Mil) and declined from Dec. 2025 ($32.52 Mil) to Mar. 2026 ($30.43 Mil).

Aura Biosciences's annual Total Liabilities increased from Dec. 2023 ($29.23 Mil) to Dec. 2024 ($30.53 Mil) and increased from Dec. 2024 ($30.53 Mil) to Dec. 2025 ($32.52 Mil).


Aura Biosciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Aura Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aura Biosciences Total Liabilities Chart

Aura Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 7.72 28.35 29.23 30.53 32.52

Aura Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.44 29.77 33.36 32.52 30.43
AURA
34GF Score
Aura Biosciences Inc AURA
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aura Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aura Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=18.383+(14.134+3.5527136788005E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=32.52

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=169.43-136.913
=32.52

Aura Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=137.677-107.247
=30.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $30.43 Mil mean?
Aura Biosciences (AURA) has a Total Liabilities of $30.43 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aura Biosciences and its competitors.
Is Aura Biosciences' Total Liabilities too high?
Aura Biosciences' current Total Liabilities is $30.43 Mil. Overall, Aura Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Aura Biosciences' Total Liabilities compare to NVCT and CADL?
Aura Biosciences' Total Liabilities of $30.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aura Biosciences and its competitors. Aura Biosciences's current Total Liabilities is $30.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aura Biosciences stock overvalued right now?
Aura Biosciences (AURA) has a current Total Liabilities of $30.43 Mil. The current Total Liabilities is $30.43 Mil. Aura Biosciences' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Aura Biosciences (AURA), the current Total Liabilities is $30.43 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aura Biosciences Business Description

Address 80 Guest Street, Boston, MA, USA, 02135
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
34GF Score

Get the complete analysis for AURA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.84
Price